<DOC>
<DOCNO>
EP-0010317
</DOCNO>
<TEXT>
<DATE>
19800430
</DATE>
<IPC-CLASSIFICATIONS>
C07C-205/00 C07D-498/00 C07F-7/18 C07F-9/00 C07D-477/20 C07D-477/26 C07C-205/42 A61K-31/40 C07F-9/568 C07F-7/00 C07D-477/00 C07D-498/04 C07D-205/00 C07D-205/08 <main>C07D-487/04</main> 
</IPC-CLASSIFICATIONS>
<TITLE>
6-, 1- and 2-substituted-1-carbapen-2-em-3-carboxylic acids, processes for the preparation of such compounds and pharmaceutical composition comprising such compounds.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc. 126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us <sep>merck & co. inc.<sep>
</APPLICANT>
<INVENTOR>
christensen burton g<sep>shih david h<sep>christensen, burton g.<sep>shih, david h.<sep>christensen, burton g.195 watchung terracescotch plains, n.j. 07076us<sep>shih, david h.9 hazel avenueedison, n.j. 08817us<sep>christensen, burton g.<sep>shih, david h.<sep>christensen, burton g.195 watchung terracescotch plains, n.j. 07076us<sep>shih, david h.9 hazel avenueedison, n.j. 08817us<sep>
</INVENTOR>
<ABSTRACT>
disclosed are 6-, 1 - and 2-substituted-1­ -carbadethiapen-2-em-3 -carboxylic acids having the struc­ ture:    wherein: r⁰ is h or -sr⁸; r¹, r⁶, r⁷ and r⁸ are, inter alia,  independently selected from the group consisting of hyd­ rogen, alkyl, alkenyl, aryl and aralkyl.  such compounds as  well as their pharmaceutically acceptable sale ester and  amide derivatives are useful as antibiotics.  also disclosed are  processes for the preparation of such compounds and phar­ maceutical compositions comprising such compounds.  
</ABSTRACT>
<DESCRIPTION>
6-, 1- and 2-substituted-1-carbadethiapen-2-em-3- carboxylic acids, processes for the preparation of such compounds and pharmaceutical composition com prising such compounds background of the invention this invention relates to 6-, 1- and 2substituted-1-carbadethiapen-2-em-3-carboxylic acids and derivatives thereof which are useful as antibiotics and which may be represented by the following generic structural formula emi1.1 wherein: r0 is h or -sr8; rú, r6, 6, r7 and 8 are independently selected from the group consisting of hydrogen, substituted and unsubstituted: alkyl, alenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; -yl, such as phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the linear chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl; wherein the substituted relative to the above-named radicals are selected fr;: the group consisting of: amino, mono, di- and trialkylamino, hydroxyl, alkoxyl, mercmpto, alkylthio, arylthio such as phenylthio, sulfamoyl, amidi, guani1: nitro, chloro, bromo, fluoro, cyano ana carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms. this invention also relates to the carboxyl derivatives of i which are antibiotics and which may be represented by the following generic structure (i): emi2.1 wherein x' is oxygen, sulphur or nr' (r' = h or lower alkyl having 1-6 carbon atoms); and r ' is, inter alia, representatively selected from the group consisting of hydrogen, conventional blocking groups such as trialkylsilyl, acyl and the pharmaceutically acceptable salt, ester and amide moieties known in the bicyclic ss-lactam antibiotic art; the definition of r3 is given in greater detail below. this z this invention also relates to processes for the preparation of such compounds (i); pharmaceutical compositions comprising such compounds; and to methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated there is a continuing need for new antibiotics. for unfortunately, there is no static effectiveness of any given antibiotic because continued wide scale usage selectively gives rise to resistant strains of pathogens. in addition, the known antibiotics suffer from the disadvantage of being effective only against certain types of microorganisms. accordingly the search for new antibiotics continues. thus, it is an objection of the present invention to provide a novel class of antibiotics which are useful in animal and human therapy and in inanimate systems. these antibiotics are active against a broad range of pathogens which representaively include both gram positive bacteria such as s. aureua, strep. pyogenes, and b. subtilis, and gram negative bacteria such as e. coli, pseudomonas, proteus morganii, serratia, and klebsiella. further objects of this invention are to provide chemical processes for the preparation of such antibiotics and their non-toxic pharmaceutically acceptable salts; pharmaceutical compositions comprising such antibiotics; and to provide methods of treatment comprising administering such antibiotics and compositions when
</DESCRIPTION>
<CLAIMS>
what is clained is      1.    .a compound having the structure: emi120.1       and the   ph¯--mscautically    acceptable salts thereof wherein r is h; pharmaceutically acceptable salt cation; or a pharmaceutically   ceptable    ester moiety; and   r1,      r6,    r7 and r8 are independently selected from the group consisting of hydrogen,   is    not h), substituted and unsubstituted:  alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moietiens; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of:  amino, mono-, di-, and trialkylamino, hydroxyl, alkoxyl, mercapto, alkylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo,   fluoro,    cyano and carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms;   ana    wherein the alkyl moieties of the above-recited   substitnt    have 1-6 carbon atoms  2.        compound according to claim 1 wherein   r1    is alkyl, or cycloalkyl.    3.   a    compound according to claim 1 wherein r6 is h or methyl and r7 is alkyl, phenyl, aralkyl or hydrohylsubstituted alkyl,pheny or aralkyl.      4. a compound according to claim 1 wherein: r6 is hydrogen or methyl and   r8 is    selected from the group consisting of: h, ch3, (ch2)2nh, c(ch3)2ch2nh2 emi121.1       emi121.2       ch2ch2ch2nh2 , ch2ch(ch3)ch2nh2 , emi121.3         emi122.1         emi123.1       ch(ch3)ch2nh2 , emi123.2       and r7 is selected from: emi123.3          -ch3 -ch2ch3 emi124.1        5. a process for preparing a compound according to claim 1 comprising:   cvclizina    in the presence of base to form: emi124.2       dehydrohalogenating   th    resulting intermediate in the presence of base to form: emi124.3       heating the resulting intermediate in the presence of a displacing agent to form: emi124.4        isomerizing the position of the double bond of the resultinq intermediate to form: emi125.1       wherein x is halo.    6. a process for preparing a compound according to claim 1 comprising treating: emi125.2       with a base capable of isomerizing the double bond to form: emi125.3       7. a compound having the structure: emi125.4       and its pharmaceutically acceptable salts and esters.     8. a compound according to   1am    the structure: emi126.1       and the pharmaceutically acceptable salts thereof wherein r is h; pharmaceutically acceptable salt cation; or a pharmaceutically   acceptable.ester    moiety; and r6, r7 and r8 are independently selected from the group consisting of hydrogen, substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of:  amino, mono-, di- and trialkylamino, hydroxyl, alkoxyl, mercapto, alkylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo, fluoro, cyano and carboxy; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms;  r1 is selected from the group consisting of methyl, ethyl1 propyl, isopropyl cyclopropyl, phenyl and   benzyl. r        9.    a compound having the structure: emi127.1       and the pharmaceutically acceptable salts and esters thereof; wherein   r1,,      and      z   rare independently selected from the group consisting; of hydrogen   (r1    is not   h) and    substituted and unsubstituted:  alkyl having 1-6 carbon atoms, phenyl, phenylalkyl wherein the alkyl moiety has   1-6    carbon atoms, cycloalkyl and cycloalkylalkyl havin3 to 6 ring carbon atoms and 1-6 carbon atoms in the alkyl moiety; wherein the   substituient    or substituents on r1, r6 and r7 are selected   from    chloro, bromo, fluoro, hydroxyl, amino, mono-, di-, and trialkylamino (each alkyl having 1-6 carbon atoms), alkoxyl having 1-6 carbon atoms, cyano and carboxyl  10. a compound according to claim 9 wherein r is alkyl, cyclopropyl, benzyl or phenyl; r6 is hydrogen and r7 is alkyl or phenylalkyl substituted by hydroxyl or amino.    11. a compound according to claim10 wherein r1 is methyl,, ethyl, isopropyl, t-butyl or phenyl and   i    is l-hydroxyethyl,   methyl,    or hydroxymethyl.      12. a process for preparing       according to claim 9 comprising treating a compound of the formula: emi128.1       wherein r is a readily removable protecting group with a glyoxylate ester wherein the ester moiety is a pharmaceutically acceptable ester moiety or a readily removable blocking group, r', to provide a compound having the structure: emi128.2       followed by halogenating to provide a compound having the structure: emi128.3       wherein x is halogen followed by treating with triphenylphosphine and mild aqueous hydrolysis to provide: emi128.4       followed by cyclizing the above structure after treating with an oxidizing agent.      ss. a process for preparing a compound according to claim 9 comprising cyclizing: emi129.1       wherein is phenyl, and r' is a pharmaceutically acceptable ester moiety or a readily removable blocking group.     14. a compound having the formula: emi130.1       and its pharmaceutically acceptable salts and esters wherein r1 is selected from the group consisting of substituted and unsubstituted loweralkyl having from 1-6 carbon atoms, phenyl, phenylloweralkyl, cycloalkyl having from 3 to 6 carbon atoms, and cycloalkylalkyl having 4 to 7 carbon atoms in the chain and 3-6 carbon atoms in the ring; wherein said substituents on r1 are selected from the group consisting of halogen, hydroxyl, amino, and substituted amino, alkoxyl, azido, cyano, carboxyl.     15. a compound according to clain 14 wherein r1 is methyl, phenyl, ethyl, cyclopropyl, propyl and isopropyl.    16. a process for preparing a compound according to claim 14 comprising treating a compound of the formula: emi130.2       wherein r is a readily removable protecting group with a glyoxylate ester wherein the ester moiety is a pharmaceutically acceptable ester moiety or a readily removable blocking group, r2, to provide a compound having the structure:    emi131.1       followed by halogenating to provide a compound having the structure: emi131.2       wherein x is halogen followed by treating with triphenylphosphine and mild aqueous hydrolysis to provide: emi131.3       followed by cyclizing the above structure after treating with an oxidizing agent.      17    a process for preparing a compound according to claim 14 comprising cyclizing: emi131.4       wherein is phenyl, and   r"    is a pharmaceutically acceptable ester moiety or a readily removable blocking group.     18. a compound having the formula: emi132.1       and its pharmace ically acceptable salts and esters wherein r1 is selected from the group consisting of substituted and unsubstituted loweralkyl having from 1-6 carbon atoms, phenyl, phenylloweralkyl, cycloalkyl having from 3 to 6 carbon atoms, and cycloalkylalkyl having 4 to 7 carbon atoms in the chain and 3-6 carbon atoms in the ring; wherein said substituents on   r1    are selected from the group consisting of halogen, hydroxyl, amino, alkoxyl-having 1-6 carbon atoms, azido, cyano, and carboxyl.    1q a compound according to claim 18 wherein r1 is methyl, phenyl, benzyl, ethyl, cyclopropyl, propyl and isopropyl.      20.    a compound according to   claim    wherein    r1    is methyl having the structure emi132.2         21.    a compound having the formula: emi132.3       wherein r is h or ch3.        22      a    process for preparing a compound according to claim 1 having the structure: emi133.1       and its pharmaceutically acceptable salts; comprising: cyclizing in the presence of base emi133.2       to torm: emi133.3       dehydrohalogenating the resulting intermediate in the presence of base to form: emi133.4       heating the resulting intermediate in the presence of a displacing agent to form: emi133.5       isomerizing the position of the double bond of the resulting intermediate to form: emi133.6       debloking to form. emi133.7           wherein r4 and r5 are blocking groups, and x is halo.    23. a process for preparing a compound   accordi    to claim   18having    the structure: emi134.1       and its pharmaceutically acceptable salts; comprising: cyclizing in the presence of bese emi134.2       to form: emi134.3       dehydrohalogenating the resulting intermediate in the presence of base to form: emi134.4       heating the resulting intermediate in   tbe    presence of a displacing agent to form: emi134.5        isomerizing the position of the double bond of the resulting intermediate to form: emi135.1       wherein r4 and   rs    are blocking groups, and x is halo.    26 a process for preparing a compound according to claim   18 having    the structure: emi135.2       comprising treating: emi135.3       with a base.capable of isomerizing the double bond to form: emi135.4       wherein r4 and r5 are blocking groups.    25. an antibiotic pharmaceutical composition comprising a therapeutically effective amount of a compound according to claims 1 to 4, 7 to 11 14, 15 or 18 to 21 and a pharmaceutically carrier therefor.         claims for @@@@ria     1. a process for preparing a compound having the structure: emi136.1       and the pharmaceutically acceptable salts thereof wherein r is h; pharmaceutically acceptable salt cation; or a pharmaceutically accetable ester moiety; and rú,r6,r7 and r8 are independently selected from the group consisting of hydrogen, (r1 is not h), substituted and unsubstituted:  alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of:  amino, mono-, di-, and trialkylamino, hydroxyl, alkoxyl, mercapto, alkylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo, fluoro, cyano and carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms comprising: cyclizing in the presence of base:   emi137.1       dehydrohalogenating the resulting intermediate in the presence of base to form: emi137.2       heating the resulting intermediate in the presence of a displacing agent to form: emi137.3       isomerizing the position of the double bond of the resulting intermediate to form: emi137.4       wherein x is halo.      2. a process for preparing a compound according to clain 1 comprising treating: emi138.1       with a base capable of isomerizing the double bond to form: emi138.2        3. a process for preparing a compound having the structure: emi138.3       and the pharmaceutically acceptable salts and esters thereof; wherein r11   r2.    and r3 are independently selected   from the group consisting of hydrogen (r1 is not h) and    substituted and unsubstituted:  alkyl having 1-6 carbon atoms, phenyl, phenylalkyl wherein the alkyl moiety has 1-6 carbon atoms, cycloalkyl and cycloalkylalkyl having 3 to 6 ring carbon atoms and 1-6 carbon atoms in the alkyl moiety; wherein the substituent or substituents on r1, r2 and r3 are selected from chloro, bromo, fluoro, hydroxyl, amino, mono-, di-, and trialkylamino (each alkyl having 1-6 carbon atoms), alkoxyl having 1-6 carbon atoms, cyano and carboxyl comprising treating a compound of the formula:   emi139.1       wherein r is a readily removable protecting group.   with a glyoxylate ester wherein the ester moiety is a pharmaceutically acceptable ester moiety or a readily removable blocking group, r', to provide a compound having the structure: emi139.2       followed by halogenating to provide a compound having the structure: emi139.3       wherein x is halogen followed by treating with triphenylphosphine and mild aqueous hydrolysis to provide: emi139.4       followed by cyclizing the above structure after treating with an oxidizing agent.      3. a process for preparing a compound according to claim 3   cc:ndrisir,g    cyclizing: emi140.1       wherein is phenyl, and r' is a pharmaceutically acceptable ester moiety or a readily removable blocking group.     5. a process for preparing a compound having the formula: emi140.2       and its pharmaceutically acceptable salts and esters wherein   r1    is selected from the group consisting of substituted and unsubstituted loweralkyl having from 1-6 carbon atoms, phenyl, phenylloweralkyl, cycloalkyl having from 3 to 6 carbon atoms, and cycloalkylalkyl having 4 to 7 carbon atoms in the chain and 3-6 carbon atoms in the ring;  wherein said substituents on r1 are selected from the group consisting of halogen, hydroxyl, amino, and substituted amino, alkoxyl, azido, cyano, carboxyl comprising treating a compound of the formula: emi140.3       wherein   r    is a   readily    removable protecting group with a glyoxylate ester wherein the ester moiety is a   pharmaceutically accetable ester moiety or a readi removable blocking group, rê , to provide a compound having the structure: emi141.1       followed by halogenating to provide a compound having the structure: emi141.2       wherein x is halogen followed by treating with triphenylphosphine and mild aqueous hydrolysis to provide: emi141.3       followed by cyclizing the above structure after treating with an oxidizing agent.      6.    a process for preparing a compound according to claim 5 comprising cyclizing: emi141.4        wherein   #    is phenyl, and rê is a pharmaceutically acceptable ester moiety or a readily removable' blocking group.    7. a process for preparing a   compound    according to claim 1 having the structure: emi142.1       and its pharmaceutically acceptable salts; comprising: cyclizing in the presence of base emi142.2       to form: emi142.3       dehydrohalogenating the resulting intermediate in the presence of base to form: emi142.4       heating the resulting intermediate in the presence of a displacing agent to form: emi142.5        isomerizing the position of the double bond of the resulting intermediate to   tor:fl:    emi143.1       deblocking to form: emi143.2       wherein r4 and r5 are blocking groups, and x is halo.    8. a process for preparing a compound having the formula: emi143.3       and its pharmaceutically acceptable salts wherein r1 is selected from the group consisting of substituted and unsubstituted loweralkyl having-from 1-6 carbon atoms, phenyl, phenylloweralkyl, cycloalkyl having from 3 to 6 carbon atoms, and cycloalkylalkyl having 4 to 7 carbon atoms in the chain and 3-6 carbon atoms in the ring; wherein said substituents on r1 are selected from the group consisting of halogen, hydroxyl, amino, alkoxyl having 1-6 carbon   atoms    azido, cyano, and carboxyl comprising:  cyclizing in the presence of base emi143.4       to form: emi143.5           dehydrohalogenating    the resulting intermediate in the presence of base to form: emi144.1       heating the resulting intermediate in the presence of    2    displacing agent to form: emi144.2       isomerizing the position of the double bond of the resulting intermediate to form: emi144.3       wherein r4 and r5 are blocking groups, and x is halo.     9. a process for preparing a   compound.having    the formula: emi144.4       wherein   r    is selected from the group consisting of substituted and unsubstituted loweralkyl having from 1-6 carbon   atop,    phenyl, phenylloweralkyl, cycloalkyl having from 3 to 6 carbon atoms, and cycloalkylalkyl having 4 to 7 carbon atoms in the chain and 3-6 carbon atoms in the ring; wherein said substituents on r1 are selected from the group consisting of halogen, hydroxyl, amino,   alkoxyl-baving    1-6 carbon atoms, azido, cyano, and carboxyl.     comprising treating. emi145.1         with a base capable of isomerizing the double bond to form: emi145.2       wherein r4 and r5 are blocking groups.  
</CLAIMS>
</TEXT>
</DOC>
